Is intravenous alteplase contraindicated when more than one-third of a cerebral hemisphere is involved?

Intravenous Alteplase and Involvement of More Than One-Third of the Cerebral Hemisphere

Intravenous alteplase is contraindicated in the 3-4.5 hour treatment window when imaging shows ischemic injury involving more than one-third of the MCA territory, but this restriction does NOT apply to the 0-3 hour window.

Time-Dependent Eligibility Criteria

The one-third MCA territory rule applies only to patients being treated in the extended 3-4.5 hour window. According to the 2018 AHA/ASA Guidelines 1111, alteplase treatment in the 3-4.5 hour window is recommended for patients who meet specific criteria including:

• Age ≤80 years
• No history of both diabetes mellitus AND prior stroke
• NIHSS score ≤25
• Not taking oral anticoagulants
• Without imaging evidence of ischemic injury involving more than one-third of the MCA territory

Critical Distinction: 0-3 Hour vs 3-4.5 Hour Windows

Within 0-3 Hours:

• No restriction based on infarct size involving one-third MCA territory
• Alteplase is indicated even for severe strokes with extensive early ischemic changes
• The guidelines explicitly state that "IV alteplase administration is recommended in the setting of early ischemic changes on NCCT of mild to moderate extent (other than frank hypodensity)" 111

Within 3-4.5 Hours:

• The one-third MCA territory restriction does apply as an exclusion criterion
• This is a Class I, Level of Evidence B-R recommendation 111

Understanding "Extensive Hypoattenuation"

The guidelines distinguish between:

1. Early ischemic changes (mild to moderate extent) - alteplase is recommended
2. Extensive regions of clear hypoattenuation/obvious hypodensity - alteplase is NOT recommended (Class III: No Benefit) 111

The guidelines note that "there remains insufficient evidence to identify a threshold of hypoattenuation severity or extent that affects treatment response to alteplase. However, administering IV alteplase to patients whose CT brain imaging exhibits extensive regions of clear hypoattenuation is not recommended. These patients have a poor prognosis despite IV alteplase, and severe hypoattenuation defined as obvious hypodensity represents irreversible injury" 111.

Clinical Algorithm

For patients presenting 0-3 hours from symptom onset:

• Proceed with alteplase regardless of one-third MCA territory involvement
• Only avoid if there is frank hypodensity/obvious irreversible injury

For patients presenting 3-4.5 hours from symptom onset:

• Do NOT give alteplase if imaging shows >1/3 MCA territory involvement
• This is an absolute exclusion criterion for this time window

Important Caveats

The one-third MCA territory rule was derived from the ECASS-3 trial, which established the 3-4.5 hour window. This exclusion criterion was part of the original trial design to minimize hemorrhagic risk in the extended window. The rationale is that larger infarcts have higher hemorrhagic transformation risk and poorer outcomes, making the risk-benefit ratio less favorable beyond 3 hours.

In the 0-3 hour window, the time-dependent benefit of alteplase is so substantial that it outweighs the increased hemorrhagic risk even in severe strokes with extensive early changes, as long as there isn't frank hypodensity indicating completed infarction.